Profiling activities of transcription factors in breast cancer cell lines

Assay and Drug Development Technologies

Volumn 4, Issue 3, 2006, Pages 293-305

  Jiang, Xin ^a   Roth, Leslie ^a   Lai, Chunfai ^a   Li, Xianqiang ^a  

^a Panomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MAX PROTEIN; MYC PROTEIN; MYOCYTE ENHANCER FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN C MYB; PROTEIN P53; SMAD3 PROTEIN; SMAD4 PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR EGR 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PIT 1;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL SPECIFICITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENETIC REGULATION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; PROTEIN MICROARRAY;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MICE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746126543     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.4.293     Document Type: Article

References (24)

1. McGuire WL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:154-155.
2. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A: Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001;358:277-286.
3. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
4. Berns A: Gene expression in diagnosis. Nature 2000;403: 491-492.
5. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217.
6. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
7. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61: 5979-5984.
8. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874.
9. Emerson BM: Specificity of gene regulation. Cell 2002;109:267-270.
10. Benz C: Transcription factors and breast cancer. Endocr Relat Cancer 1998;5:271-282.
11. Boyd KE, Farnham PJ: Identification of target genes of oncogenic transcription factors. Proc Soc Exp Biol Med 1999;222:9-28.
12. Jiang X, Norman M, Li X: Use of an array technology for profiling and comparing transcription factors activated by TNFalpha and PMA in HeLa cells. Biochim Biophys Acta 2003;1642:1-8.
13. Allred DC, Brown P, Medina D: The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004;6:240-245.
14. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME: Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13: 1558-1568.
15. Mandlekar S, Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-477.
16. Danova M, Pellicciari C, Zibera C, Mangiarotti R, Gibelli N, Giordano M, Wang E, Mazzini G, Riccardi A: Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. Ann N Y Acad Sci 1993;698:174-181.
17. Schafer JM, Bentrem DJ, Takei H, Gajdos C, Badve S, Jordan VC: A mechanism of drug resistance to tamoxifen in breast cancer. J Steroid Biochem Mol Biol 2002;83:75-83.
18. Louie MC, Zou JX, Rabinovich A, Chen HW: ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004;24:5157-5171.
19. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S, Kushner PJ: The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999;13:1672-1685.
20. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D: Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem 2003;278:11802-11810.
21. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996;272:719-722.
22. Clottes E: [Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy]. Bull Cancer 2005;92:119-127.
23. Schafer JM, Lee ES, O'Regan RM, Yao K, Jordan VC: Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 2000;6:4373-4380.
24. Johansson EM, Kannius-Janson M, Gritli-Linde A, Bjursell G, Nilsson J: Nuclear factor 1-C2 is regulated by prolactin and shows a distinct expression pattern in the mouse mammary epithelial cells during development. Mol Endocrinol 2005;19:992-1003.